ArticleThe Kaohsiung journal of medical sciences2024

Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung.

Chia-Yu Kuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.